AZ-SION-POWER
7.12.2022 19:42:35 CET | Business Wire | Press release
Sion Power Corporation, a leading technology developer of next-generation batteries for electric vehicles (EV), today announced plans to expand its existing manufacturing operations in Tucson, Arizona. The planned expansion site is the 111,400-square-foot building at 6950 South Country Club Road.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221207005770/en/
Sion Power's SP-1 expansion site. (Photo: Business Wire)
The expansion is expected to be complete by 2026 and create over 150 jobs. New jobs will primarily be engineering, skilled technicians, and other manufacturing-related positions. The overall economic impact of the expansion is $341 million over the next five years. Sion Power’s headquarters will remain in its nearby location at 2900 East Elvira Road, doubling its footprint.
Sion Power chose to expand because of its rich history, access and the availability of quality and skilled employees in the Tucson community. Since its inception as a small group of researchers for next-generation batteries, the company has been in Tucson. Now Sion Power has over 100 employees and is scaling up its ultra-high energy, lithium-metal based Licerion® battery development.
“The global construction of battery manufacturing plants is occurring at a rapid pace, and the United States can’t be left behind,” said Mr. Tracy Kelley, CEO of Sion Power. Mr. Kelley went on to say, “With our facility expansion in Tucson, Arizona, it will allow Sion Power to further our mission of scaling battery manufacturing from research and development to commercialization. This enables us to better serve our customers and their applications.”
Sion Power’s facility expansion will be equipped with fully automated battery cell production capabilities, including proprietary lithium metal anode manufacturing, cell assembly, and testing.
The critical component of the company’s battery is the proprietary anode technology, which is a key differentiator and enabler within the next-generation rechargeable battery market and is capable of delivering up to 500 Wh/kg.
Project partners include the Arizona Commerce Authority, Pima County, City of Tucson, and Sun Corridor Inc. Potential City of Tucson incentives are under review and subject to final approval by Council.
“Sion Power’s expansion further emphasizes Arizona’s global leadership in battery and EV technologies,” Sandra Watson, president and CEO of the Arizona Commerce Authority. “We are excited Sion Power will continue its impressive legacy in Tucson, manufacturing batteries for electric vehicles while expanding Arizona’s battery supply chain.”
“Sion Power has been a valued business in Pima County for many years,” said Sharon Bronson, chair, Pima County Board of Supervisors. “The County works hard to ensure local companies have the workforce they need, and we thank Sion for their continued investment in our region. Congratulations to Tracy and the entire team for this achievement.”
“I want to congratulate Sion Power and CEO Tracy Kelley on their latest plans for expansion,” said Tucson Mayor Regina Romero. “Tucson is a national leader in EV readiness and a growing hub for battery manufacturing in the Southwest. Together, we are creating hundreds of high-wage green jobs and elevating Tucson’s reputation as a leader in climate action,” added Romero.
“Beyond business attraction, another critical aspect to economic development success is to help local headquarter companies like Sion Power expand,” said Joe Snell, president & CEO of Sun Corridor Inc. “We’re thrilled to see this expansion include innovative and next-gen technologies that offer high-skilled jobs to our community.”
Sion Power’s expansion highlights the state’s growing battery industry and supply chain. Within the last few years, companies such as Li-Cycle, LG and KORE Power have commenced or announced operations throughout the state.
About Sion Power Corporation
Sion Power advances the rechargeable battery industry with its Licerion® technology. Licerion® is an advanced approach to lithium-metal batteries containing twice the energy in the same size and weight battery, compared to a traditional lithium-ion battery. At up to 500 Wh/kg, Licerion batteries are produced at scale in large-format cells. As a result, Licerion® batteries have the potential to significantly enhance the performance of commercial and consumer electric vehicles. Visit Sion Power on the web at sionpower.com.
About the Arizona Commerce Authority
The Arizona Commerce Authority (ACA) is the state's leading economic development organization with a streamlined mission to grow and strengthen Arizona's economy. The ACA uses a three-pronged approach to advance the overall economy: attract, expand, create - attract out-of-state companies to establish operations in Arizona; work with existing companies to expand their business in Arizona and beyond; and help entrepreneurs create new Arizona businesses in targeted industries. For more information, please visit azcommerce.com and follow the ACA on Twitter @azcommerce.
About Sun Corridor Inc.
Sun Corridor Inc. is a transformative economic development organization representing one of the most dynamic and growing major business centers in North America. Located in Southern Arizona and encompassing four counties (Pinal, Pima, Santa Cruz and Cochise), Sun Corridor Inc. is a CEO-driven regional alliance whose members aggressively champion mega-regional issues that impact economic competitiveness and quality of life. The organization has helped to drive significant business investment into the Tucson and Southern Arizona region through primary job creation, resulting in an economic impact of $32 billion. Learn more at suncorridorinc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221207005770/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom